|
|
||||||||
-sarcoglycanopathy)From INSERM U 153 (Drs. Eymard, Romero, Thémar-Noël, Tomé, and Fardeau, and H. Collin), Institut de Myologie, Hôpital de la Salpêtnère, Paris; INSERM U 129 & Hôpital Cochin (Drs. Leturcq, Piccolo, Jeanpierre, and Kaplan, hnd A. Carrié and N. Deburgrave), Paris; Hôpital Bologhine (Dr. Azibi), Alger; Hôpital Ben-Aknoun (Dr. Chaouch), Alger; Instituto Ortopedico Rizzoli (Dr. Merlini), Bologna; CHU (Dr. Penisson), Angers; Hôpital Saint Vincent de Paul (Dr. Mayer), Paris; CHU (Dr. Tanguy), Clermont-Ferrand; and the Howard Hughes Medical Institute and Department of Physiology and Biophsics (Dr. Campbell), University of Iowa College of Medicine, Iowa City, IA.
Primary adhalin (or a-sarcoglycan) deficiency due to a defect of the adhalin gene 1ocaIized on chromosome 17q21 causes an autosomal recessive myopathy. We evaluated 20 patients from 15 families (12 from Europe and three from North Africa) with a primary adhalin deficiency with two objectives: characterization of the clinical phenotype and analysis of the correlation with the level of adhalin expression and the type of gene mutation. Age at onset and seventy of the myopathy were heterogeneous: six patients were wheel-chair bound before 15 years of age, whereas five other patients had mild disease with preserved ambulation in adulthood. The clinical pattern was similar in all the patients with symmetric characteristic involvement of trunk and limb muscles, calf hypertrophy, and absence of cardiac dysfunction. Immunofluorescence and immunoblot studies of muscle biopsy specimens showed a large variation in the expression of adhalin. The degree of adhalin deficiency was fairly correlated with the clinical severity. There were 15 different mutations (10 missense, five null). Double null mutations (three patients) were associated with severe myopathy, but in the other cases (null/missense and double missense) there was a large variation in the severity of the disease.
This article has been cited by other articles:
![]() |
A Y Manzur and F Muntoni Diagnosis and new treatments in muscular dystrophies Postgrad. Med. J., November 1, 2009; 85(1009): 622 - 630. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Y Manzur and F Muntoni Diagnosis and new treatments in muscular dystrophies J. Neurol. Neurosurg. Psychiatry, July 1, 2009; 80(7): 706 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, C. Long, Y. Yue, and D. Duan Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice Hum. Mol. Genet., April 1, 2009; 18(7): 1209 - 1220. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Rodino-Klapac, J-S Lee, R. C. Mulligan, K. R. Clark, and J. R. Mendell Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D Neurology, July 22, 2008; 71(4): 240 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kobuke, F. Piccolo, K. W. Garringer, S. A. Moore, E. Sweezer, B. Yang, and K. P. Campbell A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in mice Hum. Mol. Genet., May 1, 2008; 17(9): 1201 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bartoli, E. Gicquel, L. Barrault, T. Soheili, M. Malissen, B. Malissen, N. Vincent-Lacaze, N. Perez, B. Udd, O. Danos, et al. Mannosidase I inhibition rescues the human {alpha}-sarcoglycan R77C recurrent mutation Hum. Mol. Genet., May 1, 2008; 17(9): 1214 - 1221. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Filosto, P. Tonin, G. Vattemi, L. Bertolasi, A. Simonati, N. Rizzuto, and G. Tomelleri The role of muscle biopsy in investigating isolated muscle pain Neurology, January 16, 2007; 68(3): 181 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Shahrizaila, W J M Kinnear, and A J Wills Respiratory involvement in inherited primary muscle conditions J. Neurol. Neurosurg. Psychiatry, October 1, 2006; 77(10): 1108 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
E S Moreira, M Vainzof, O T Suzuki, R C M Pavanello, M Zatz, and M R Passos-Bueno Genotype-phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations J. Med. Genet., February 1, 2003; 40(2): e12 - 12. [Full Text] [PDF] |
||||
![]() |
P. Laforet, M. Nicolino, B. Eymard, J. P. Puech, C. Caillaud, L. Poenaru, and M. Fardeau Juvenile and adult-onset acid maltase deficiency in France: Genotype-phenotype correlation Neurology, October 24, 2000; 55(8): 1122 - 1128. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Crosbie, L. E. Lim, S. A. Moore, M. Hirano, A. P. Hays, S. W. Maybaum, H. Collin, S. A. Dovico, C. A. Stolle, M. Fardeau, et al. Molecular and genetic characterization of sarcospan: insights into sarcoglycan-sarcospan interactions Hum. Mol. Genet., August 12, 2000; 9(13): 2019 - 2027. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Y. Chan, W T Hung, A Wong, E Hu, and R G Beran Validating a screening questionnaire for parkinsonism in Australia J. Neurol. Neurosurg. Psychiatry, July 1, 2000; 69(1): 117 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Barresi, C. Di Blasi, T. Negri, R. Brugnoni, A. Vitali, G. Felisari, A. Salandi, S. Daniel, F. Cornelio, L. Morandi, et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations J. Med. Genet., February 1, 2000; 37(2): 102 - 107. [Abstract] [Full Text] |
||||
![]() |
K. M. D. Bushby Making sense of the limb-girdle muscular dystrophies Brain, August 1, 1999; 122(8): 1403 - 1420. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. North NEW PERSPECTIVES IN PEDIATRIC NEUROMUSCULAR DISORDERS Hotel Intercontinental Sydney, Sydney, Australia, August 28, 1998 J Child Neurol, January 1, 1999; 14(1): 26 - 57. [PDF] |
||||
![]() |
C. Angelini, M. Fanin, M. P. Freda, D. J. Duggan, G. Siciliano, and E. P. Hoffman The clinical spectrum of sarcoglycanopathies Neurology, January 1, 1999; 52(1): 176 - 176. [Abstract] [Full Text] |
||||
![]() |
L. V. B. Anderson, K. Davison, J. A. Moss, I. Richard, M. Fardeau, F. M. S. Tome, C. Hubner, A. Lasa, J. Colomer, and J. S. Beckmann Characterization of Monoclonal Antibodies to Calpain 3 and Protein Expression in Muscle from Patients with Limb-Girdle Muscular Dystrophy Type 2A Am. J. Pathol., October 1, 1998; 153(4): 1169 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Duclos, V. Straub, S. A. Moore, D. P. Venzke, R. F. Hrstka, R. H. Crosbie, M. Durbeej, C. S. Lebakken, A. J. Ettinger, J. van der Meulen, et al. Progressive Muscular Dystrophy in {alpha}-Sarcoglycan-deficient Mice J. Cell Biol., September 21, 1998; 142(6): 1461 - 1471. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |